The United Kingdom Private GP EHR Market is expected to grow in the future due to the rising demand for private GP services, technological advancements in healthcare, and regulations promoting secure patient data storage. However, cyber-attacks and technical issues pose some limitations to the adoption and growth of this market.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
